Fig 1: Quantification of serum levels of tenascin-C (TNC) and cellular communication network factor 3 (CCN3) in the 85% partial hepatectomy (PHx) rat group and the 90% PHx rat group. (A) Serum TNC levels in the 85% PHx group (broken line) and the 90% PHx group (solid line). (B) Serum CCN3 levels in the 85% PHx group (broken line) and the 90% PHx group (solid line). ** p<0.01.
Fig 2: Receiver operating characteristic (ROC) curves and area under the curve (AUC) for serum measurement of tenascin-C (TNC) and cellular communication network factor 3 (CCN3) for the diagnosis of post hepatectomy liver failure (PHLF). (A) ROC curve analysis for TNC levels for the diagnosis of PHLF at postoperative day 3. (B) ROC curve analysis for CCN3 levels for the diagnosis of PHLF at postoperative day 3.
Fig 3: Perioperative tenascin-C (TNC) and cellular communication network factor 3 (CCN3) levels in 50 patients with post hepatectomy liver failure (PHLF) at increasing time points. (A) Perioperative TNC levels before (Pre), and day 1 (d1), and at day 3 (d3) after liver resection. (B) Perioperative CCN3 levels before (Pre), and at day 1 (d1), and day 3 (d3) after liver resection. (C) and (D) show the patients stratified as those with and without post hepatectomy liver failure (PHLF). * p<0.05, ** p<0.01.
Fig 4: Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for tenascin-C (TNC) and cellular communication network factor 3 (CCN3) in the 85% partial hepatectomy (PHx) rat group and the 90% PHx rat group. (A) The quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for hepatic TNC mRNA in the 85% PHx group (broken line) and the 90% PHx group (solid line). (B) The qRT-PCR for CCN3 mRNA in the 85% PHx group (broken line) and the 90% PHx group (solid line). * p<0.05, ** p<0.01.
Supplier Page from Abcam for Mouse NOV ELISA Kit (CCN3)